Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Receivables (2021 - 2025)

Historic Change in Receivables for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to -$62000.0.

  • Silence Therapeutics' Change in Receivables fell 10344.04% to -$62000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$383000.0, marking a year-over-year decrease of 10191.01%. This contributed to the annual value of $904000.0 for FY2024, which is 33061.22% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Change in Receivables is -$62000.0, which was down 10344.04% from $8000.0 recorded in Q2 2025.
  • Silence Therapeutics' Change in Receivables' 5-year high stood at $46.5 million during Q2 2021, with a 5-year trough of -$13.8 million in Q2 2023.
  • For the 5-year period, Silence Therapeutics' Change in Receivables averaged around $3.0 million, with its median value being $8000.0 (2025).
  • In the last 5 years, Silence Therapeutics' Change in Receivables crashed by 324358.73% in 2023 and then surged by 115872.42% in 2024.
  • Silence Therapeutics' Change in Receivables (Quarter) stood at -$2.5 million in 2021, then skyrocketed by 62.53% to -$920748.6 in 2022, then surged by 131.54% to $290429.5 in 2023, then skyrocketed by 110.38% to $611000.0 in 2024, then tumbled by 110.15% to -$62000.0 in 2025.
  • Its last three reported values are -$62000.0 in Q3 2025, $8000.0 for Q2 2025, and -$940000.0 during Q1 2025.